Sign in
CompletedPhase 4

Association Between Diastolic Dysfunction and Erectile Dysfunction and the Effect of Tadalafil and SGLT2 Inhibitors on Them in Men With Metabolic Syndrome

Key facts

Who runs it
Kafrelsheikh University
Where
Egypt1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 4
People taking part
60 people enrolled
Started
5 May 2025
Ended
17 Mar 2026
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Tadalafil 5 mg
  • SGLT-2 inhibitor
  • Tadalafil plus SGLT2 inhibitors
Record updated
4 May 2026

Who can take part

Age
18 years and older
Sex
Men only
Healthy volunteers
Cannot take part
Show the full registry criteria (5)Hide the full registry criteria

Who can take part

  • Male patients aged ≥18 years
  • History of sexual activity within the past 6 months
  • Erectile dysfunction for at least 3 months (defined as IIEF-6 score ≤25)
  • Diagnosed with metabolic syndrome

Who cannot take part

  • * Left ventricular systolic dysfunction (EF less than 50%); Recent myocardial infarction (within 1 month); Moderate to severe valvular heart disease (stenosis or regurgitation); Renal failure (eGFR <20 ml/min); Major pelvic surgery; Significant central nervous system injury (e.g., spinal cord injury); Endocrine disorders (hypothyroidism, hypogonadism); Premature ejaculation; Current balanitis or urogenital infections; History of orthostatic hypotension; Any contraindications to tadalafil or SGLT2 inhibitors

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Metabolic syndrome is associated with an increased risk of cardiovascular disease and is commonly accompanied by erectile dysfunction and subclinical cardiac dysfunction. Erectile dysfunction and left ventricular diastolic dysfunction may share common underlying mechanisms, including endothelial dysfunction and microvascular impairment.

Read full original descriptionShow less

This study aims to investigate the association between erectile dysfunction and left ventricular diastolic dysfunction in men with metabolic syndrome, and to evaluate the effects of different treatment strategies, including tadalafil and SGLT2 inhibitors, on both erectile function and cardiac diastolic function.

Participants will be randomly assigned to receive tadalafil, an SGLT2 inhibitor, or a combination of both for a duration of three months. Clinical, echocardiographic, and functional assessments will be performed at baseline and after treatment.

The results of this study may improve understanding of the link between cardiovascular and sexual dysfunction and help guide therapeutic approaches in this patient population.

The 3 groups in the trial

  • Tadalafil GroupExisting treatment, for comparison

    Participants received tadalafil 5 mg orally once daily for 3 months. Erectile function, left ventricular diastolic function, and metabolic parameters were assessed at baseline and after completion of treatment.

    Treatment: Tadalafil 5 mg

  • SGLT2 inhibitors groupTreatment being tested

    Participants received SGLT2 inhibitors (dapagliflozin or empagliflozin) 10 mg orally once daily for 3 months. Erectile function, left ventricular diastolic function, and metabolic parameters were assessed at baseline and after completion of treatment.

    Treatment: SGLT-2 inhibitor

  • Combination therapyTreatment being tested

    Participants received combination therapy with tadalafil 5 mg once daily plus SGLT2 inhibitors 10 mg once daily for 3 months. Erectile function, left ventricular diastolic function, and metabolic parameters were assessed at baseline and after completion of treatment.

    Treatment: Tadalafil plus SGLT2 inhibitors

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized, Allocation-concealed, Assessor-blinded, Parallel-group Trial Evaluating the Association Between Erectile Dysfunction and Left Ventricular Diastolic Dysfunction and Comparing the Effects of Tadalafil, SGLT2 Inhibitors, and Their Combination in Patients With Metabolic Syndrome.
Record updated
4 May 2026